



ResQ Biotech

Rescuing humanity from
protein misfolding diseases
through innovations in biotechnology

What we do | Develop new drugs against protein misfolding diseases

Well-folded protein



Healthy state



Misfolded protein



Disease state



Why target protein misfolding diseases?

*“Enormous demand
for effective therapeutics”*

Why target protein misfolding diseases?


*“Enormous demand
for effective therapeutics”*

50+
diseases
of this type

Why target protein misfolding diseases?

“Enormous demand for effective therapeutics”

50+ diseases
of this type




High socioeconomic impact



Why target protein misfolding diseases?

“Enormous demand for effective therapeutics”

50+ diseases
of this type



High socioeconomic impact



Currently incurable
(vast majority)



ResQ Biotech | Facts & Mission

ResQ Biotech | Facts & Mission

- ❑ A spin-off company of the National Hellenic Research Foundation
- ❑ Founded in 2019 at Patras Science Park

ResQ Biotech | Facts & Mission

- ❑ A spin-off company of the National Hellenic Research Foundation
- ❑ Founded in 2019 at Patras Science Park
- ❑ An early-stage drug discovery company
- ❑ Target diseases caused by protein misfolding

ResQ Biotech | Facts & Mission

- ❑ A spin-off company of the National Hellenic Research Foundation
- ❑ Founded in 2019 at Patras Science Park
- ❑ An early-stage drug discovery company
- ❑ Target diseases caused by protein misfolding
- ❑ Perform **early** drug discovery & **pre-clinical** development
- ❑ License the developed compounds to larger pharma companies to initiate clinical studies

**ResQ Biotech |
Exploiting the power of
Biotechnology**

ResQ Biotech vs. classic drug discovery



- ❑ **Tens of billions** of test compounds vs. few millions
- ❑ The bacteria **themselves identify the bioactives**
- ❑ Initial discovery in a **culture tube** vs. huge facilities
- ❑ Initial discovery in **days** vs. years
- ❑ **\$0.00004 vs. \$1,100** per compound
- ❑ **New molecular entities** vs. same old
- ❑ Multiple screens for **different targets simultaneously** vs. one at a time

Brief Bio



- BSc, Chemical Engineering,
**National Technical University
of Athens, Greece (1993-1998)**

Brief Bio



- BSc, Chemical Engineering, **National Technical University of Athens**, Greece (1993-1998)
- PhD, Chemical & Biological Engineering, **Princeton University**, USA (1999-2005)

Brief Bio



- BSc, Chemical Engineering, **National Technical University of Athens**, Greece (1993-1998)
- PhD, Chemical & Biological Engineering, **Princeton University**, USA (1999-2005)
- Post-doc, Institute for Cell & Molecular Biology, **University of Texas at Austin**, USA (2006-2009)





Brief Bio



- BSc, Chemical Engineering, **National Technical University of Athens**, Greece (1993-1998)
- PhD, Chemical & Biological Engineering, **Princeton University**, USA (1999-2005)
- Post-doc, Institute for Cell & Molecular Biology, **University of Texas at Austin**, USA (2006-2009)
- Principal Investigator, Institute of Chemical Biology, **National Hellenic Research Foundation**, Greece (2010-present)
[Research Associate Professor]



PRINCETON
UNIVERSITY





PRINCETON
UNIVERSITY



Laboratory of Enzyme & Synthetic Biotechnology National Hellenic Research Foundation



Laboratory of Enzyme & Synthetic Biotechnology National Hellenic Research Foundation



NATIONAL HELLENIC
RESEARCH FOUNDATION



John S. Latsis
Public Benefit Foundation

Laboratory of Enzyme & Synthetic Biotechnology National Hellenic Research Foundation



NATIONAL HELLENIC
RESEARCH FOUNDATION



John S. Latsis
Public Benefit Foundation



Lab funding acquired: > 3 million €

ResQ Biotech | Contact

Georgios Skretas |



gskretas@eie.gr

Dafni Delivoria |



dafnidelivoria@gmail.com

Athina Ikonomidou |



athikonomidou@gmail.com

